Close Menu

NEW YORK – Dutch biotech startup Epify announced today that it has raised €500,000 ($547,000) in seed funding.

The firm will use the funding to develop a portfolio of biomarkers discovered by Maastricht University professor Manon van Engeland to detect colorectal cancer (CRC). Founded by Engeland, Epify anticipates offering the biomarkers for non-invasive diagnosis of CRC at the earliest stage possible to allow patients to benefit from therapeutic interventions while they are still healthy.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.